Journal
PERSONALIZED MEDICINE
Volume 13, Issue 4, Pages 303-314Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pme-2016-0009
Keywords
16p11.2 CNV; genomic disorders; incidental findings; population biobank; return of results
Categories
Funding
- European Social Fund's Doctoral Studies and Internationalisation Programme DoRa (Foundation Archimedes)
- Swiss Scientific Exchange NMS Program
- SNSF [31003A_160203]
- Simons Foundation Autism Research Initiative [SFARI274424]
- Center of Excellence in Genomics (EXCEGEN)
- University of Tartu (SP1GVARENG)
- FP7 grant BBMRI-LPC [313010]
- Estonian and European Research (infrastructure) Roadmap grant [3.2.0304.11-0312]
- Estonian Research Council [IUT20-60]
Ask authors/readers for more resources
Background: Procedural guidelines for disclosure of incidental genomic information are lacking. Methods: We introduce a method and evaluated the impact of returning results to population biobank participants with 16p11.2 copy number variants, which are commonly associated with neurodevelopmental disorders and BMI imbalance. Of the 7877 participants, 11 carriers were detected. Eight participants were informed of their carrier status and surveyed 11-17 months later. Results: All participants demonstrated preference for disclosure. Although two participants experienced worry, all five survey respondents rated receiving this information favorably. One participant reported modifications in treatment and three felt that their treatment/condition had since improved. Conclusion: This approach can be adapted and applied for the return of incidental findings to biobank participants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available